As such, except for CA19-9, Maspin, pVHL, MUC1, MUC5AC, IMP3, S100P, Mesothelin found in Liu et al.’s review, the other IHC biomarkers in the current review are potential diagnostic tools for pancreatic cancer that have been validated during the period of 2013 up to now. This evidence concerns the gene SERPINB5 and familial pancreatic carcinoma.